One of two of Opthea's phase III trials for a common eye disease has failed to meet its objectives, casting doubts on the ...

The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

Thanks to the spending growth cap, the U.K. government in December 2024 announced that companies would need to pay a 22.9% ...

Companies have been battling with a lack of private investment in recent years but could now face a lack of government funds.

Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

Weekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 study Systemic exposure following subcutaneous administration ...

The US joins Moldova, Hong Kong, and New Zealand as countries to greenlight the company's Phase I trial of PBGENE-HBV.

A revolutionary new drug trial called LION aims to ravage the ... a cancer immunologist from the Cancer Research UK Manchester Institute, University of Manchester. With plans to recruit 89 ...

Two criminals involved in a Hatton Garden money laundering scheme have been jailed after attempting to smuggle £190million worth of drugs into the UK and wash the proceeds through London's iconic ...

The first of the SKYNET 6 assets, 6A, has reached a milestone with the completion of the initial phase of testing at the new UK-government funded National Satellite Test Facility (NSTF) in Harwell, ...